Related Experiment Videos
Lamivudine/zidovudine/abacavir: triple combination tablet
Tim Ibbotson1, Caroline M Perry
1Adis International Limited, Mairangi Bay, Auckland, New Zealand.
Drugs
|May 17, 2003
Summary
A new triple combination tablet with lamivudine, zidovudine, and abacavir demonstrates comparable efficacy to other antiretroviral regimens in HIV treatment. This combination therapy shows similar viral load reduction and virological failure rates in both treatment-naive and experienced patients.
Area of Science:
- Infectious Diseases
- Virology
- Pharmacology
Background:
- Nucleoside analogue reverse transcriptase inhibitors (NRTIs) are a cornerstone of HIV treatment.
- Fixed-dose combination antiretroviral therapy simplifies treatment regimens.
- Assessing the efficacy and safety of novel NRTI combinations is crucial for optimizing HIV management.
Purpose of the Study:
- To evaluate the efficacy of a new triple combination tablet containing lamivudine, zidovudine, and abacavir.
- To compare the efficacy of this triple combination with existing antiretroviral regimens in treatment-naive and treatment-experienced HIV patients.
- To assess virological failure rates and adverse events associated with the triple combination therapy.
Main Methods:
- Two studies were conducted in treatment-naive patients: one double-blind and one nonblind.
- Treatment-naive patients received lamivudine/zidovudine plus abacavir.
- Treatment-experienced patients with suppressed viral load (<50 copies/mL) were switched to the lamivudine/zidovudine/abacavir triple combination tablet.
Main Results:
- In treatment-naive patients, the triple combination showed efficacy similar to lamivudine/zidovudine plus indinavir, with comparable plasma HIV RNA levels at week 48 (51% vs 51% and 64% vs 50%).
- In treatment-experienced patients, switching to the triple combination was as effective as maintaining protease inhibitor-based highly active antiretroviral treatment.
- Virological failure (HIV RNA >400 copies/mL) occurred in 22% of patients in both groups at week 48.
- Common adverse events in treatment-naive patients included nausea, malaise/fatigue, and vomiting.
Conclusions:
- The lamivudine/zidovudine/abacavir triple combination tablet is an effective antiretroviral treatment option.
- This fixed-dose combination demonstrates comparable efficacy to other regimens in achieving viral suppression and preventing virological failure.
- Adverse events such as nausea and fatigue were observed in treatment-naive patients receiving this combination.